Current Report Filing (8-k)
August 15 2016 - 7:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 15, 2016
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
000-54986
|
46-0524102
|
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
Framingham, Massachusetts
|
01702
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On August 15, 2016, Arch Therapeutics, Inc. (the “
Company
”)
issued a press release announcing the results of the Company’s recently completed clinical trial in Western Europe using
the AC5 Topical Hemostatic Device™. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated
by reference herein.
|
Item 9.01
|
Financial Statements and Exhibit
|
(d) Exhibits
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued by Arch Therapeutics, Inc. on August 15, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
Dated: August 15, 2016
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
Name: Terrence W. Norchi, M.D.
|
|
Title: President, Chief Executive Officer
|
Exhibit
List
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued by Arch Therapeutics, Inc. on August 15, 2016
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Apr 2023 to Apr 2024